The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
CONTACT:
Recruiting: Hamilton ON, Ottawa ON, Toronto ON, Montreal QC
Phone Number:
844-434-4210
Email: Participate-In-This-Study@its.jnj.com